These individuals need supplementation and regular monitoring to prevent deficiency from developing over months to years of treatment
Spiekerkoetter U, Huener G, Baykal T, Demirkol M, Duran M, Wanders R, Nezu J, Mayatepek E: Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2
The microsomes were incubated with 500 M solutions of Dihexa, piroxicam, verapamil, and 7-ethoxycoumarin, as controls for low, moderate, and highly metabolized compounds, respectively, in 0.1 M Tris buffer with an NADPH-regenerating system at 37C
Manufacturers often explore delivery methods like liposomes or nanoparticles to enhance oral bioavailability